ChemoMetec A/S (CPH:CHEMM)

Market Cap	7.05B -23.0%
Revenue (ttm)	493.12M +7.3%
Net Income	177.03M +4.7%
EPS	10.17 +4.6%
Shares Out	17.40M
PE Ratio	39.82
Forward PE	32.76
Dividend	7.00 (1.73%)
Ex-Dividend Date	Oct 10, 2025

Volume	33,601
Open	404.40
Previous Close	405.00
Day's Range	393.80 - 404.40
52-Week Range	235.20 - 804.00
Beta	1.36
Analysts	Strong Buy
Price Target	546.25 (+37.25%)
Earnings Date	Sep 10, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 172
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: CHEMM

Financial Performance

In fiscal year 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Analyst Summary

According to 4 analysts, the average rating for CHEMM stock is "Strong Buy." The 12-month stock price target is kr 546.25, which is an increase of 37.25% from the latest price.

Price Target

kr 546.25

(37.25% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 8, 2026

Data Sources Report a data error